Wall Street brokerages expect Kadmon Holdings Inc (NYSE:KDMN) to announce earnings per share (EPS) of ($0.26) for the current quarter, Zacks reports. Three analysts have issued estimates for Kadmon’s earnings, with the lowest EPS estimate coming in at ($0.26) and the highest estimate coming in at ($0.25). Kadmon reported earnings of ($0.44) per share during the same quarter last year, which indicates a positive year over year growth rate of 40.9%. The firm is scheduled to report its next earnings report on Thursday, August 9th.
According to Zacks, analysts expect that Kadmon will report full year earnings of ($0.96) per share for the current year, with EPS estimates ranging from ($1.00) to ($0.91). For the next financial year, analysts forecast that the company will report earnings of ($1.00) per share, with EPS estimates ranging from ($1.10) to ($0.89). Zacks’ EPS averages are a mean average based on a survey of sell-side analysts that follow Kadmon.
Kadmon (NYSE:KDMN) last posted its quarterly earnings data on Tuesday, May 8th. The company reported ($0.27) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.30) by $0.03. The firm had revenue of $0.43 million during the quarter, compared to the consensus estimate of $2.67 million.
KDMN opened at $3.27 on Monday. Kadmon has a one year low of $2.06 and a one year high of $5.86.
Institutional investors and hedge funds have recently bought and sold shares of the company. Acuta Capital Partners LLC raised its stake in shares of Kadmon by 21.1% in the 1st quarter. Acuta Capital Partners LLC now owns 5,950,000 shares of the company’s stock worth $25,288,000 after buying an additional 1,035,000 shares in the last quarter. Spark Investment Management LLC raised its position in shares of Kadmon by 55.5% during the first quarter. Spark Investment Management LLC now owns 373,000 shares of the company’s stock worth $1,585,000 after purchasing an additional 133,200 shares during the period. Sofinnova Ventures Inc acquired a new stake in shares of Kadmon during the first quarter worth $794,000. Asymmetry Capital Management L.P. acquired a new stake in shares of Kadmon during the first quarter worth $846,000. Finally, Wells Fargo & Company MN raised its position in shares of Kadmon by 38.5% during the fourth quarter. Wells Fargo & Company MN now owns 102,418 shares of the company’s stock worth $370,000 after purchasing an additional 28,462 shares during the period. 64.11% of the stock is currently owned by institutional investors.
Kadmon Company Profile
Kadmon Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. The company markets and distributes a portfolio of branded generic ribavirin products for chronic hepatitis C virus infection; and distributes products in various therapeutic areas, including tetrabenazine for the treatment of chorea associated with Huntington's disease.
Further Reading: Diversification Important in Investing
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kadmon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon and related companies with MarketBeat.com's FREE daily email newsletter.